Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
Notes underwriting agrmnt
|
|
Kura Oncology, Inc. (KURA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/03/2017 |
8-K
| Form 8-K - Current report |
| 10/14/2015 |
8-K
| Appointed a new director |
| 04/27/2015 |
8-K
| Appointed a new director|
Docs:
|
"FAHEEM HASNAIN JOINS KURA ONCOLOGY BOARD OF DIRECTORS LA JOLLA, April 27, 2015 - Kura Oncology, Inc. , a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the appointment of Faheem Hasnain to the Company's board of directors. Mr. Hasnain brings more than 20 years of experience in the pharmaceutical and biotechnology industries, with executive leadership and board roles at leading public companies, including Receptos, Ambit, Facet Biotech Corporation, PDL BioPharma, Biogen Idec, Bristol Myers-Squibb and GlaxoSmithKline. “Faheem is a distinguished leader in the biopharmaceutical industry, one who has successfully guided both emerging biotech and major pharmaceutical companies,” said Troy W..." |
|
|
|